Decoding Haematological Toxicity Associated with Antibody-Drug Conjugates: Mechanisms, Clinical Profiles and Management Strategies
Antibody-drug conjugates (ADCs) improve targeted drug delivery but are often associated with hematological toxicity. This review examines the structural, mechanistic and clinical evidence on ADC-induced hematological toxicity, focusing on approved ADCs and strategies for dose adjustment. Approved ADCs, including Gemtuzumab Ozogamicin (GO), Inotuzumab Ozogamicin (IO), trastuzumab emtansine, brentuximab vedotin, Polatuzumab Vedotin (PV), Sacituzumab Govitecan (SG), trastuzumab deruxtecan, Enfortumab Vedotin (EV), tisotumab vedotin, Loncastuximab Tesirine (LT), belantamab mafodotin, mirvetuximab soravtansine and disitamab vedotin, exhibit distinct hematological toxicity profiles. Common adverse events include neutropenia, thrombocytopenia, anemia, leukopenia, lymphopenia and febrile neutropenia. These toxicities are influenced by factors such as antigen distribution, linker stability, payload characteristics, drug-to-antibody ratio, Fc receptor-mediated uptake and nonspecific endocytosis. Management strategies include dose interruption or reduction, growth factor support, transfusions and regular laboratory monitoring. Hematological toxicity is an important factor affecting the tolerability of ADCs. Understanding the mechanisms underlying these toxicities is essential for improving their clinical management and guiding the development of safer next-generation ADCs.
Authors
- Jaini Patel (ORCID: https://orcid.org/0000-0003-3784-3688)
- Samarth R Rathod (ORCID: https://orcid.org/0009-0005-6262-4905)
- Amar M. Raval (ORCID: https://orcid.org/0009-0005-1409-1745)
- DR. AASTHA UKANI (ORCID: https://orcid.org/0009-0006-0536-362X)
- Ashok Kumar (ORCID: https://orcid.org/0009-0009-0295-1807)
Publication Details
- Journal
- Pharmacology and Toxicology Research
- Published
- 2026-11-13
- DOI
- https://doi.org/10.68163/ptr.2026.76
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00